TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04930432: A Phase I/II Study of MCLA-129, a Human Anti-EGFR and Anti-c-Met Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors, Evaluating Safety, Pharmacokinetic Characteristics and Antitumor Activity

Sponsor: Betta Pharmaceuticals Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,675,900

Rescue Site Savings

+$4,398,240

Unlock Full NCT04930432 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04930432 Rescue Dossier →